CD47-CAR-T cells

CD47-CAR-T cells represent a novel form of chimeric antigen receptor (CAR) T-cell therapy engineered to target the CD47 protein, which is frequently overexpressed on the surface of various cancer cells. CD47 acts as an immune checkpoint, specifically a "don't eat me" signal, by binding to signal regulatory protein alpha (SIRPα) on macrophages and dendritic cells, thereby inhibiting phagocytosis and allowing tumor cells to evade immune surveillance. By expressing a CAR specific for CD47, these engineered T cells aim to directly recognize and eliminate CD47-positive cancer cells and/or disrupt the CD47-SIRPα interaction, thereby promoting macrophage-mediated phagocytosis of tumor cells. This therapeutic strategy is being investigated for its potential to treat a range of hematological and solid tumors, including ovarian, pancreatic, and lung cancers, with ongoing preclinical research exploring methods to enhance their efficacy and overcome challenges such as T-cell fratricide or systemic toxicity associated with CD47 blockade.